文献速递浆细胞疾病

芦可替尼通过下调PD-L1表达逆转多发性骨髓瘤免疫检查点抑制

Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
PubMed 文献 · Br J Haematol · 2020-12-20

该研究探讨JAK抑制剂芦可替尼(RUX)对多发性骨髓瘤(MM)细胞PD-L1表达及T细胞抗肿瘤活性的影响。结果显示MM进展期患者骨髓单个核细胞PD-L1基因表达显著高于完全缓解者,RUX浓度依赖性降低MM肿瘤细胞PD-L1表达,并增强IL-2刺激T细胞诱导的MM细胞凋亡,效果与抗PD-1/PD-L1抗体相当。

要点

  • MM进展期患者骨髓单个核细胞PD-L1基因表达显著高于完全缓解者
  • RUX浓度依赖性降低MM肿瘤细胞PD-L1表达,共培养基质细胞时亦如此
  • RUX增强IL-2刺激T细胞对MM细胞的凋亡诱导,程度与抗PD-1/PD-L1抗体相似

核心结论

  • RUX可阻断PD-L1表达,从而增强T细胞对MM细胞的抗肿瘤效应。

研究设计与样本

  • 体外研究:比较MM患者骨髓单个核细胞PD-L1基因表达,并检测RUX单独或与抗MM药物联用对MM肿瘤细胞PD-L1表达及T细胞毒性的影响。

主要发现

  • MM进展期患者骨髓单个核细胞PD-L1基因表达较完全缓解者显著升高。
  • RUX处理使单独培养或与基质细胞共培养的MM肿瘤细胞PD-L1基因表达呈浓度依赖性降低。
  • RUX在IL-2刺激T细胞存在下增加MM细胞凋亡,程度与抗PD-1或抗PD-L1抗体治疗相似。

临床怎么用

  • RUX可能通过下调PD-L1增强T细胞抗MM活性,为联合免疫治疗提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) tumour cells evade host immunity through a variety of mechanisms, which may potentially include the programmed cell death ligand-1 (PD-L1):programmed cell death protein-1 (PD-1) axis. This interaction contributes to the immunosuppressive bone marrow (BM) microenvironment, ultimately leading to reduced effector cell function. PD-L1 is overexpressed in MMBM and is associated with the resistance to immune-based approaches for treating MM. Ruxolitinib (RUX), an inhibitor of the Janus kinase (JAK) family of protein tyrosine kinases, is approved for myeloproliferative diseases. We investigated the effects of RUX alone or in combination with anti-MM agents on the expression of PD-L1 and T-cell cytotoxicity in MM. We showed that the expression of the PD-L1 gene was markedly increased in BM mononuclear cells from patients with MM with progressive disease versus those in complete remission. Furthermore, RUX treatment resulted in a concentration-dependent reduction of PD-L1 gene expression in the MM tumour cells cultured alone or co-cultured with stromal cells compared with untreated cells. The results also demonstrated that RUX increased MM cell apoptosis in the presence of interleukin-2-stimulated T cells to a similar degree as the treatment with anti-PD-1 or anti-PD-L1 antibodies. In summary, these results indicate that RUX can block PD-L1 expression resulting in augmentation of anti-MM effects of T cells.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chen H, Li M, Ng N, et al. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. Br J Haematol. 2020. PMID: 33341940. doi:10.1111/bjh.17282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。